Advertisement

Peritoneal-plasma barrier

  • Pierre Jacquet
  • Paul H. Sugarbaker
Part of the Cancer Treatment and Research book series (CTAR, volume 82)

Abstract

Intraperitoneal chemotherapy has been described as a therapeutic option in the management of a variety of malignancies that occur primarily in a locoregional manner [1]. Potential benefits of this technique may occur in tumors principally confined to the peritoneal cavity (gastrointestinal malignancies and ovarian carcinoma) [2,3]. Theoretically, the use of intraperitoneal drug could eliminate local tumor spread as a mechanism of cancer recurrence both in the abdomen and in the pelvis.

Keywords

Peritoneal Cavity Peritoneal Carcinomatosis Mesothelial Cell Peritoneal Fluid Continuous Ambulatory Peritoneal Dialysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Spratt JS, Edwards M, Kubota T, Lindberg R, Tseng MT. Peritoneal carcinomatosis: Anatomy, physiology, diagnosis and management. Curr Prol Cancer 1986;10:553–584.CrossRefGoogle Scholar
  2. 2.
    Sugarbaker PH, Cunliffe W, Belliveau J, et al. Rationale for early postoperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy. Reg Cancer Treat 1989;1:66–79.Google Scholar
  3. 3.
    Markman M, Howell SB, Lucas WE, Pfeifle CE, Green MR. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, doxorubicin for refractoy ovarian carcinoma and other malignancies principally confiend to the peritoneal cavity. J Clin Oncol 1984;2: 1321–1325.PubMedGoogle Scholar
  4. 4.
    Jacquet P, Vidal-Jove J, Zhu B, Sugarbaker PH. Peritoneal carcinomatosis from gastrointestinal malignacy: Natural history and new prospects for management. Acta Chir Belg 1994;94:191–197.PubMedGoogle Scholar
  5. 5.
    Sugarbaker PH. Cytoreductive approach to peritoneal carcinomatosis: Peritonectomy and intraperitoneal chemotherapy. In Postgraduate Advances in Colorectal Surgery. Forum Medicum, 1991, II-X.Google Scholar
  6. 6.
    Esperanda MJ, Collins DL. Peritoneal dialysis efficiency in relaion to body weight. J Pediatr Sur 1966;1:162–169.CrossRefGoogle Scholar
  7. 7.
    Pfeiffer CJ, Pfeiffer DC, Misra HP. Enteric serosal surface in the piglet. A scanning and transmission electron microscopic study of the mesothelium. J Submicrosc Cytol 1987; 19: 237–246.PubMedGoogle Scholar
  8. 8.
    Waiters WB, Buck RC. Scanning electron microscopy of mesothelial regeneration in the rat. Lab Invest 1972;26:604–609.Google Scholar
  9. 9.
    Kruger S, Greve DW, Schueler FW. Absorption of fluid from peritoneal cavity. Arch Int Pharmacodyn Ther 1962;137:173–178.PubMedGoogle Scholar
  10. 10.
    Yoffey JM, Courtice FC. Lymphatics, Lymph and the Lymphomyeloid Complex. London: Academic Press, 1970;206–231.Google Scholar
  11. 11.
    Greenwalt D, Nakamura RM, diZerega G. Determination of pH and pKa in human peritoneal fluid. Curr Surg 1988;45:217–218.Google Scholar
  12. 12.
    Aune S. Transperitoneal exchange IV. The effect of transperitoneal fluid transport on the transfer of solutes. Scand J Gastroenterol 1970;5:241–252.PubMedGoogle Scholar
  13. 13.
    Torres IG, Litterest CL, Guarino AM. Transport of model compounds across the peritoneal menbrane in the rat. Pharmacology 1987;17:330–340.CrossRefGoogle Scholar
  14. 14.
    Fedorko ME, Hirsch JG, Studies on transport of macromolecules and small particles across the mesothelial cells of the mouse omentum. I. Morphological aspects. Exp Cell Res 1971;69:113–127.PubMedCrossRefGoogle Scholar
  15. 15.
    Lukas G, Brindle SD, Greengerd P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 1971;178:562–566.PubMedGoogle Scholar
  16. 16.
    Rippe B, Stelin G. Peritoneal transport of water and solutes. Proceedings of Peritoneum and Peritoneal Access. Lund: Sweden, 1987, p 41.Google Scholar
  17. 17.
    Arnaud JP, Adolf M. Physiopathologie du péritoine. Péritonisation-drainage. In Encycl Med Chir Techniques chirurgicales, Appareil digestif. Paris: 1989(11);40070: 15.Google Scholar
  18. 18.
    Leak LV, Rahil K. Permeability of the diaphragmatic mesothelium:the ultrastructural basis for stromata. Am J Anat 1978;151:557–594.PubMedCrossRefGoogle Scholar
  19. 19.
    Lill SR, Parsons RH, Buchac I. Permeability of the diaphragma nd fluid resorption from the peritoneal cavity in the rat. Gastroenterology 1979;76:997–1002.PubMedGoogle Scholar
  20. 20.
    Flessner ME, Fenstermacher JD, Blasberg RG, et al. Peritoneal absorption of macro-molecules studied by quantitative autoradiography. Am J Physiol 1985;248:26–32.Google Scholar
  21. 21.
    Sugarbaker PH, Cunliffe WJ, Belliveau J, de Cruijn EA, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989;16:83–97.PubMedGoogle Scholar
  22. 22.
    Gross ML, Somani P, Ribner BS, Raeader R, et al. Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983;34:673–680.PubMedCrossRefGoogle Scholar
  23. 23.
    Keller E, Reetze, P, Schollmeyer P. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 1900;18:104–117.CrossRefGoogle Scholar
  24. 24.
    Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 1985;12:1–6.PubMedGoogle Scholar
  25. 25.
    Flessner MF, Dedrick RL, Schultz JS. A distributed model of peritoneal-plasma transport: Analysis of experimental data in the rat. Am J Physiol 1985;248:F413-F424.PubMedGoogle Scholar
  26. 26.
    Rubin J, Jones Q, Planch A, Bower JD. The minimal importance of the hollow viscera to peritoneal transport during peritoneal dialysis in the rat. Am Soc Artif Intern Organs Transact 1988;34:912–915.Google Scholar
  27. 27.
    Sugarbaker PH, Klecker RW, Gianola FJ, Speyer JL. Prolonged treatment schedules with intraperitoneal 5-fluorouracil diminish the loco-regional naure of drug distribution. Am J Clin Oncol 1986;9:1–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Sugarbaker PH, Stuart OA, Vidal-Jove J, Pessagno AM, DeBruijn EA. Studies of the peritonea-plasma barrier after systemic mitomycin C administration. Reg Cancer Treat 1993;4:188–194.Google Scholar
  29. 29.
    Maher JF. Physiology of the peritoneum. Implications for peritoneal dialysis. Med Clin North Am 1990;74(4):985–996.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1996

Authors and Affiliations

  • Pierre Jacquet
  • Paul H. Sugarbaker

There are no affiliations available

Personalised recommendations